



FOR IMMEDIATE RELEASE:

Bioniche Life Sciences Inc. to Provide an Update on Vaccine Manufacturing Centre Validation

BELLEVILLE, ON, June 27, 2013 – Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC) today announced that it will be hosting a:

**Conference Call & Audio Webcast
Tuesday, July 9, 2013
6:00 p.m. ET**

Company representatives will provide an update on GMP validation of its Animal Health and Food Safety Vaccine Manufacturing Centre in Belleville, Ontario.

To participate in the conference call from North America, call (888) 231-8191 (conference ID: 13113047).

To participate in the conference call from Australia, call 1-800-287-011 (conference ID: 13113047).

A listen-only audio webcast will be available at:

<http://event.on24.com/r.htm?e=653147&s=1&k=562F01AE2A898EFCF88998DC1602D956>

A replay of the conference call will be available until July 16, 2013 at midnight by calling 1-855-859-2056 (passcode: 13113047).

The webcast will be available for replay using the above link until July 8, 2014.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

For further information, please contact:

Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.

Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058

Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097

Jennifer.Shea@Bioniche.com